Details of the Drug

General Information of Drug (ID: DMGFPU2)

Drug Name
Linezolid
Synonyms
Linezlid; ZLD; Zyvox; Zyvoxa; Zyvoxam; Zyvoxid; PNU 100766; U 100766; Linezolid & VRC3375; Linezolid [USAN:INN]; PNU-100766; U-100766; Zyvox (TN); Zyvoxam (TN); Zyvoxid (TN); NDA 21-130 Zyvox (linezolid tablets); NDA 21-131 Zyvox for injection (linezolid injection); NDA 21-132 Zyvox oral suspension (linzolid oral suspension); Linezolid (JAN/USAN/INN); PNU-100766, U-100766, Zyvoxid, Zyvoxam, Linezolid; N-((3-(3-fluoro-4-morpholinylphenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide; N-(((S)-3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide; N-[[(5S)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide; N-({5S)-3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide, N-[[(S)-3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl]methyl]acetamide; (S)-N-[[3-(3-fluoro-4-morpholinylphenyl)-2-oxo-5-oxazolidinyl]methyl]acetamide; 111GE017
Indication
Disease Entry ICD 11 Status REF
Bacterial infection 1A00-1C4Z Approved [1]
Therapeutic Class
Antibiotics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 337.35
Topological Polar Surface Area (xlogp) 0.7
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [2]
Bioavailability
99% of drug becomes completely available to its intended biological destination(s) [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 1.8 mL/min/kg [4]
Elimination
30% of drug is excreted from urine in the unchanged form [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 4.5 hours [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 50.8162 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.69% [4]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.58 L/kg [4]
Water Solubility
The ability of drug to dissolve in water is measured as 8 mg/mL [2]
Chemical Identifiers
Formula
C16H20FN3O4
IUPAC Name
N-[[(5S)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
Canonical SMILES
CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F
InChI
InChI=1S/C16H20FN3O4/c1-11(21)18-9-13-10-20(16(22)24-13)12-2-3-15(14(17)8-12)19-4-6-23-7-5-19/h2-3,8,13H,4-7,9-10H2,1H3,(H,18,21)/t13-/m0/s1
InChIKey
TYZROVQLWOKYKF-ZDUSSCGKSA-N
Cross-matching ID
PubChem CID
441401
ChEBI ID
CHEBI:63607
CAS Number
165800-03-3
DrugBank ID
DB00601
TTD ID
D07UYO
VARIDT ID
DR00748
ACDINA ID
D00367

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial 23S ribosomal RNA (Bact 23S rRNA) TTLFGBV NOUNIPROTAC Binder [6]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Linezolid (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Methylene blue DMJAPE7 Major Additive serotonergic effects by the combination of Linezolid and Methylene blue. Acquired methaemoglobinaemia [3A93] [15]
Repaglinide DM5SXUV Moderate Increased risk of hypoglycemia by the combination of Linezolid and Repaglinide. Acute diabete complication [5A2Y] [16]
Glibenclamide DM8JXPZ Moderate Increased risk of hypoglycemia by the combination of Linezolid and Glibenclamide. Acute diabete complication [5A2Y] [16]
Tolazamide DMIHRNA Moderate Increased risk of hypoglycemia by the combination of Linezolid and Tolazamide. Acute diabete complication [5A2Y] [16]
Nateglinide DMLK2QH Moderate Increased risk of hypoglycemia by the combination of Linezolid and Nateglinide. Acute diabete complication [5A2Y] [16]
Insulin-glulisine DMQI0FU Moderate Increased risk of hypoglycemia by the combination of Linezolid and Insulin-glulisine. Acute diabete complication [5A2Y] [16]
Insulin-aspart DMX7V28 Moderate Increased risk of hypoglycemia by the combination of Linezolid and Insulin-aspart. Acute diabete complication [5A2Y] [17]
Glipizide DMZA5PQ Moderate Increased risk of hypoglycemia by the combination of Linezolid and Glipizide. Acute diabete complication [5A2Y] [16]
Epinephrine DM3KJBC Major Additive hypertensive effects by the combination of Linezolid and Epinephrine. Allergic/hypersensitivity disorder [4A80-4A8Z] [18]
Mepyramine DMB4SFH Moderate Additive CNS depression effects by the combination of Linezolid and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [19]
Phenyltoloxamine DMKAEQW Moderate Additive CNS depression effects by the combination of Linezolid and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [19]
Tripelennamine DMZBU15 Moderate Additive CNS depression effects by the combination of Linezolid and Tripelennamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [19]
Isosorbide dinitrate DMBI4JG Moderate Additive hypotensive effects by the combination of Linezolid and Isosorbide dinitrate. Anal fissure/fistula [DB50] [20]
Trimethaphan DMHF4IQ Moderate Additive hypotensive effects by the combination of Linezolid and Trimethaphan. Aneurysm/dissection [BD50] [21]
Bepridil DM0RKS4 Moderate Additive hypotensive effects by the combination of Linezolid and Bepridil. Angina pectoris [BA40] [20]
Amyl nitrite DMJKO05 Moderate Additive hypotensive effects by the combination of Linezolid and Amyl nitrite. Angina pectoris [BA40] [20]
Nifedipine DMSVOZT Moderate Additive hypotensive effects by the combination of Linezolid and Nifedipine. Angina pectoris [BA40] [20]
Levalbuterol DM5YBO1 Moderate Additive hypertensive effects by the combination of Linezolid and Levalbuterol. Asthma [CA23] [22]
Terbutaline DMD4381 Moderate Additive hypertensive effects by the combination of Linezolid and Terbutaline. Asthma [CA23] [23]
Pirbuterol DMI5678 Moderate Additive hypertensive effects by the combination of Linezolid and Pirbuterol. Asthma [CA23] [23]
Ephedrine DMMV0KW Major Increased risk of hyperpyrexia by the combination of Linezolid and Ephedrine. Asthma [CA23] [18]
Salbutamol DMN9CWF Moderate Additive hypertensive effects by the combination of Linezolid and Salbutamol. Asthma [CA23] [22]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Linezolid and Roflumilast. Asthma [CA23] [24]
Formoterol DMSOURV Moderate Additive hypertensive effects by the combination of Linezolid and Formoterol. Asthma [CA23] [23]
Lisdexamfetamine DM6W8V5 Major Additive hypertensive effects by the combination of Linezolid and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [20]
Desipramine DMT2FDC Major Additive serotonergic effects by the combination of Linezolid and Desipramine. Attention deficit hyperactivity disorder [6A05] [25]
Droxidopa DM5YF4M Moderate Additive hypertensive effects by the combination of Linezolid and Droxidopa. Autonomic nervous system disorder [8D87] [26]
Pseudoephedrine DMIVJ0D Major Increased risk of hyperpyrexia by the combination of Linezolid and Pseudoephedrine. Breathing abnormality [MD11] [18]
Olodaterol DM62B78 Moderate Additive hypertensive effects by the combination of Linezolid and Olodaterol. Chronic obstructive pulmonary disease [CA22] [23]
Vilanterol DMF5EK1 Moderate Additive hypertensive effects by the combination of Linezolid and Vilanterol. Chronic obstructive pulmonary disease [CA22] [22]
Salmeterol DMIEU69 Moderate Additive hypertensive effects by the combination of Linezolid and Salmeterol. Chronic obstructive pulmonary disease [CA22] [23]
Indacaterol DMQJHR7 Moderate Additive hypertensive effects by the combination of Linezolid and Indacaterol. Chronic obstructive pulmonary disease [CA22] [23]
Arformoterol DMYM974 Moderate Additive hypertensive effects by the combination of Linezolid and Arformoterol. Chronic obstructive pulmonary disease [CA22] [23]
Levomilnacipran DMV26S8 Major Additive serotonergic effects by the combination of Linezolid and Levomilnacipran. Chronic pain [MG30] [25]
Isoproterenol DMK7MEY Moderate Additive hypertensive effects by the combination of Linezolid and Isoproterenol. Conduction disorder [BC63] [22]
Cocaine DMSOX7I Major Increased risk of hyperpyrexia by the combination of Linezolid and Cocaine. Corneal disease [9A76-9A78] [27]
Remifentanil DMZTXCH Major Additive serotonergic effects by the combination of Linezolid and Remifentanil. Corneal disease [9A76-9A78] [28]
Mycophenolic acid DMU65NK Moderate Altered absorption of Linezolid due to GI flora changes caused by Mycophenolic acid. Crohn disease [DD70] [29]
Cyclandelate DMO0R76 Moderate Additive hypotensive effects by the combination of Linezolid and Cyclandelate. Dementia [6D80-6D8Z] [20]
Sertraline DM0FB1J Major Additive serotonergic effects by the combination of Linezolid and Sertraline. Depression [6A70-6A7Z] [25]
Trimipramine DM1SC8M Major Additive serotonergic effects by the combination of Linezolid and Trimipramine. Depression [6A70-6A7Z] [25]
Nefazodone DM4ZS8M Major Additive serotonergic effects by the combination of Linezolid and Nefazodone. Depression [6A70-6A7Z] [25]
Paroxetine DM5PVQE Major Additive serotonergic effects by the combination of Linezolid and Paroxetine. Depression [6A70-6A7Z] [25]
Selegiline DM6034S Major Additive serotonergic effects by the combination of Linezolid and Selegiline. Depression [6A70-6A7Z] [30]
Vortioxetine DM6F1PU Major Additive serotonergic effects by the combination of Linezolid and Vortioxetine. Depression [6A70-6A7Z] [25]
Isocarboxazid DMAF1NB Major Additive hypertensive effects by the combination of Linezolid and Isocarboxazid. Depression [6A70-6A7Z] [30]
Milnacipran DMBFE74 Major Additive serotonergic effects by the combination of Linezolid and Milnacipran. Depression [6A70-6A7Z] [25]
Escitalopram DMFK9HG Major Additive serotonergic effects by the combination of Linezolid and Escitalopram. Depression [6A70-6A7Z] [25]
Tranylcypromine DMGB5RE Major Additive hypertensive effects by the combination of Linezolid and Tranylcypromine. Depression [6A70-6A7Z] [30]
Desvenlafaxine DMHD4PE Major Additive serotonergic effects by the combination of Linezolid and Desvenlafaxine. Depression [6A70-6A7Z] [25]
Phenelzine DMHIDUE Major Additive hypertensive effects by the combination of Linezolid and Phenelzine. Depression [6A70-6A7Z] [30]
Clomipramine DMINRKW Major Additive serotonergic effects by the combination of Linezolid and Clomipramine. Depression [6A70-6A7Z] [25]
Trazodone DMK1GBJ Major Additive serotonergic effects by the combination of Linezolid and Trazodone. Depression [6A70-6A7Z] [25]
Doxepin DMPI98T Major Additive serotonergic effects by the combination of Linezolid and Doxepin. Depression [6A70-6A7Z] [25]
Maprotiline DMPWB7T Major Additive serotonergic effects by the combination of Linezolid and Maprotiline. Depression [6A70-6A7Z] [25]
Esketamine DMVU687 Major Additive hypertensive effects by the combination of Linezolid and Esketamine. Depression [6A70-6A7Z] [31]
Nitroglycerin DMQ2491 Moderate Additive hypotensive effects by the combination of Linezolid and Nitroglycerin. Diabetic foot ulcer [BD54] [20]
5-hydroxy-L-tryptophan DMDWZGJ Major Additive serotonergic effects by the combination of Linezolid and 5-hydroxy-L-tryptophan. Discovery agent [N.A.] [15]
LEVONORDEFRIN DMWDJ0H Major Additive hypertensive effects by the combination of Linezolid and LEVONORDEFRIN. Discovery agent [N.A.] [18]
Tetrabenazine DMYWQ0O Major Additive hypertensive effects by the combination of Linezolid and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [32]
Deutetrabenazine DMUPFLI Major Additive hypertensive effects by the combination of Linezolid and Deutetrabenazine. Dystonic disorder [8A02] [32]
Oxcarbazepine DM5PU6O Major Additive serotonergic effects by the combination of Linezolid and Oxcarbazepine. Epilepsy/seizure [8A61-8A6Z] [15]
Guanabenz DM5QWEL Moderate Additive hypotensive effects by the combination of Linezolid and Guanabenz. Essential hypertension [BA00] [20]
Guanethidine DM9NSWT Moderate Antagonize the effect of Linezolid when combined with Guanethidine. Essential hypertension [BA00] [33]
Nicardipine DMCDYW7 Moderate Additive hypotensive effects by the combination of Linezolid and Nicardipine. Essential hypertension [BA00] [20]
Mephentermine DMFJH5Q Major Additive hypertensive effects by the combination of Linezolid and Mephentermine. Essential hypertension [BA00] [18]
Mecamylamine DMGQFYB Moderate Additive hypotensive effects by the combination of Linezolid and Mecamylamine. Essential hypertension [BA00] [20]
Oxymetazoline DM8ZXT6 Moderate Decreased metabolism of Linezolid caused by Oxymetazoline mediated inhibition of non-CYP450 enzyme. Eyelid inflammatory disorder [9A02] [34]
Phentolamine DMXYJOB Moderate Additive hypotensive effects by the combination of Linezolid and Phentolamine. Gangrene [MC85] [20]
Ergotamine DMKR3C5 Major Additive serotonergic effects by the combination of Linezolid and Ergotamine. Headache [8A80-8A84] [28]
Dobutamine DMD1B8Z Major Additive hypertensive effects by the combination of Linezolid and Dobutamine. Heart failure [BD10-BD1Z] [18]
Eplerenone DMF0NQR Moderate Additive hypotensive effects by the combination of Linezolid and Eplerenone. Heart failure [BD10-BD1Z] [20]
Nesiritide DMFOIA8 Moderate Additive hypotensive effects by the combination of Linezolid and Nesiritide. Heart failure [BD10-BD1Z] [20]
Chlorothiazide DMLHESP Moderate Additive hypotensive effects by the combination of Linezolid and Chlorothiazide. Heart failure [BD10-BD1Z] [20]
Furosemide DMMQ8ZG Moderate Additive hypotensive effects by the combination of Linezolid and Furosemide. Heart failure [BD10-BD1Z] [20]
Bumetanide DMRV7H0 Moderate Additive hypotensive effects by the combination of Linezolid and Bumetanide. Heart failure [BD10-BD1Z] [20]
Hydroflumethiazide DMVPUQI Moderate Additive hypotensive effects by the combination of Linezolid and Hydroflumethiazide. Heart failure [BD10-BD1Z] [20]
Tetrahydrozoline DMT57WC Moderate Decreased metabolism of Linezolid caused by Tetrahydrozoline mediated inhibition of non-CYP450 enzyme. Herpes simplex infection [1F00] [34]
Procarbazine DMIK367 Major Additive hypertensive effects by the combination of Linezolid and Procarbazine. Hodgkin lymphoma [2B30] [30]
Brentuximab vedotin DMWLC57 Moderate Increased risk of peripheral neuropathy by the combination of Linezolid and Brentuximab vedotin. Hodgkin lymphoma [2B30] [35]
Zalcitabine DMH7MUV Moderate Increased risk of peripheral neuropathy by the combination of Linezolid and Zalcitabine. Human immunodeficiency virus disease [1C60-1C62] [36]
Maraviroc DMTL94F Moderate Additive hypotensive effects by the combination of Linezolid and Maraviroc. Human immunodeficiency virus disease [1C60-1C62] [20]
Isosorbide mononitrate DMYLMU0 Moderate Additive hypotensive effects by the combination of Linezolid and Isosorbide mononitrate. Hydrocephalus [8D64] [20]
Teriflunomide DMQ2FKJ Major Additive myelosuppressive effects by the combination of Linezolid and Teriflunomide. Hyper-lipoproteinaemia [5C80] [37]
Eprosartan DM07K2I Moderate Additive hypotensive effects by the combination of Linezolid and Eprosartan. Hypertension [BA00-BA04] [20]
Aliskiren DM1BV7W Moderate Additive hypotensive effects by the combination of Linezolid and Aliskiren. Hypertension [BA00-BA04] [20]
Moexipril DM26E4B Moderate Additive hypotensive effects by the combination of Linezolid and Moexipril. Hypertension [BA00-BA04] [20]
Captopril DM458UM Moderate Additive hypotensive effects by the combination of Linezolid and Captopril. Hypertension [BA00-BA04] [20]
Methyldopa DM5I621 Major Decreased metabolism of Linezolid caused by Methyldopa mediated inhibition of non-CYP450 enzyme. Hypertension [BA00-BA04] [33]
Losartan DM72JXH Moderate Additive hypotensive effects by the combination of Linezolid and Losartan. Hypertension [BA00-BA04] [20]
Levamlodipine DM92S6N Moderate Additive hypotensive effects by the combination of Linezolid and Levamlodipine. Hypertension [BA00-BA04] [20]
Verapamil DMA7PEW Moderate Additive hypotensive effects by the combination of Linezolid and Verapamil. Hypertension [BA00-BA04] [20]
Methoxamine DMF5XQH Major Increased risk of hyperpyrexia by the combination of Linezolid and Methoxamine. Hypertension [BA00-BA04] [18]
Fenoldopam DMFAOKP Moderate Additive hypotensive effects by the combination of Linezolid and Fenoldopam. Hypertension [BA00-BA04] [20]
Indapamide DMGN1PW Moderate Additive hypotensive effects by the combination of Linezolid and Indapamide. Hypertension [BA00-BA04] [20]
Trichlormethiazide DMHAQCO Moderate Additive hypotensive effects by the combination of Linezolid and Trichlormethiazide. Hypertension [BA00-BA04] [20]
Diazoxide DML1538 Moderate Additive hypotensive effects by the combination of Linezolid and Diazoxide. Hypertension [BA00-BA04] [20]
Perindopril DMOPZDT Moderate Additive hypotensive effects by the combination of Linezolid and Perindopril. Hypertension [BA00-BA04] [20]
Felodipine DMOSW35 Moderate Additive hypotensive effects by the combination of Linezolid and Felodipine. Hypertension [BA00-BA04] [20]
Quinapril DMR8H31 Moderate Additive hypotensive effects by the combination of Linezolid and Quinapril. Hypertension [BA00-BA04] [20]
Deserpidine DMRH7CV Moderate Additive hypertensive effects by the combination of Linezolid and Deserpidine. Hypertension [BA00-BA04] [38]
Hydralazine DMU8JGH Moderate Additive hypotensive effects by the combination of Linezolid and Hydralazine. Hypertension [BA00-BA04] [20]
Lisinopril DMUOK4C Moderate Additive hypotensive effects by the combination of Linezolid and Lisinopril. Hypertension [BA00-BA04] [20]
Hydrochlorothiazide DMUSZHD Moderate Additive hypotensive effects by the combination of Linezolid and Hydrochlorothiazide. Hypertension [BA00-BA04] [20]
Clevidipine butyrate DMW4M97 Moderate Additive hypotensive effects by the combination of Linezolid and Clevidipine butyrate. Hypertension [BA00-BA04] [20]
Metaraminol DMWIX23 Major Additive hypertensive effects by the combination of Linezolid and Metaraminol. Hypotension [BA20-BA21] [18]
Propiomazine DMKY8V1 Moderate Additive hypotensive effects by the combination of Linezolid and Propiomazine. Insomnia [7A00-7A0Z] [20]
Naphazoline DMJFZDL Moderate Decreased metabolism of Linezolid caused by Naphazoline mediated inhibition of non-CYP450 enzyme. Itching [1F28-1G07] [34]
Denosumab DMNI0KO Moderate Additive myelosuppressive effects by the combination of Linezolid and Denosumab. Low bone mass disorder [FB83] [39]
Almogran DM7I64Z Major Additive serotonergic effects by the combination of Linezolid and Almogran. Migraine [8A80] [25]
Frovatriptan DM7RE8P Major Additive serotonergic effects by the combination of Linezolid and Frovatriptan. Migraine [8A80] [25]
Rizatriptan DMDJMA3 Major Additive serotonergic effects by the combination of Linezolid and Rizatriptan. Migraine [8A80] [25]
Naratriptan DMO50U2 Major Additive serotonergic effects by the combination of Linezolid and Naratriptan. Migraine [8A80] [25]
Sumatriptan DMVYXR8 Major Additive serotonergic effects by the combination of Linezolid and Sumatriptan. Migraine [8A80] [25]
Lasmiditan DMXLVDT Major Additive serotonergic effects by the combination of Linezolid and Lasmiditan. Migraine [8A80] [25]
Thalidomide DM70BU5 Moderate Increased risk of peripheral neuropathy by the combination of Linezolid and Thalidomide. Multiple myeloma [2A83] [36]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Linezolid and Tecfidera. Multiple sclerosis [8A40] [40]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Linezolid and Fingolimod. Multiple sclerosis [8A40] [41]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Linezolid and Ocrelizumab. Multiple sclerosis [8A40] [42]
Ozanimod DMT6AM2 Major Decreased metabolism of Linezolid caused by Ozanimod mediated inhibition of non-CYP450 enzyme. Multiple sclerosis [8A40] [43]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive immunosuppressive effects by the combination of Linezolid and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [44]
Dextroamphetamine DMMIHVP Major Increased risk of hyperpyrexia by the combination of Linezolid and Dextroamphetamine. Narcolepsy [7A20] [20]
Phenindamine DMDTC7R Moderate Additive CNS depression effects by the combination of Linezolid and Phenindamine. Nasopharyngitis [CA00] [19]
Promethazine DM6I5GR Moderate Additive hypotensive effects by the combination of Linezolid and Promethazine. Nausea/vomiting [MD90] [20]
Cyclizine DM9G7BS Moderate Additive CNS depression effects by the combination of Linezolid and Cyclizine. Nausea/vomiting [MD90] [19]
Metoclopramide DMFA5MY Moderate Increased risk of hyperpyrexia by the combination of Linezolid and Metoclopramide. Nausea/vomiting [MD90] [45]
Dolasetron DMMG26Z Major Additive serotonergic effects by the combination of Linezolid and Dolasetron. Nausea/vomiting [MD90] [19]
Ondansetron DMOTQ1I Major Additive serotonergic effects by the combination of Linezolid and Ondansetron. Nausea/vomiting [MD90] [19]
Phendimetrazine DM6TS1N Major Increased risk of hyperpyrexia by the combination of Linezolid and Phendimetrazine. Obesity [5B80-5B81] [20]
Amfepramone DM9YSNQ Major Increased risk of hyperpyrexia by the combination of Linezolid and Amfepramone. Obesity [5B80-5B81] [20]
Benzphetamine DMIJATC Major Increased risk of hyperpyrexia by the combination of Linezolid and Benzphetamine. Obesity [5B80-5B81] [20]
Dexfenfluramine DMJ7YDS Major Additive serotonergic effects by the combination of Linezolid and Dexfenfluramine. Obesity [5B80-5B81] [25]
Propylhexedrine DMTBW2O Moderate Decreased metabolism of Linezolid caused by Propylhexedrine mediated inhibition of non-CYP450 enzyme. Obesity [5B80-5B81] [34]
Polythiazide DMCH80F Moderate Additive hypotensive effects by the combination of Linezolid and Polythiazide. Oedema [MG29] [20]
Lofexidine DM1WXA6 Moderate Additive hypotensive effects by the combination of Linezolid and Lofexidine. Opioid use disorder [6C43] [20]
Apraclonidine DMO4PVE Major Additive hypertensive effects by the combination of Linezolid and Apraclonidine. Optic nerve disorder [9C40] [38]
Methamphetamine DMPM4SK Major Increased risk of hyperpyrexia by the combination of Linezolid and Methamphetamine. Pain [MG30-MG3Z] [46]
Safinamide DM0YWJC Major Additive serotonergic effects by the combination of Linezolid and Safinamide. Parkinsonism [8A00] [30]
Rasagiline DM3WKQ4 Major Additive serotonergic effects by the combination of Linezolid and Rasagiline. Parkinsonism [8A00] [30]
Levodopa DMN3E57 Major Additive hypertensive effects by the combination of Linezolid and Levodopa. Parkinsonism [8A00] [20]
Dopamine DMPGUCF Major Additive hypertensive effects by the combination of Linezolid and Dopamine. Parkinsonism [8A00] [18]
Ritodrine DM4V6RL Moderate Additive hypertensive effects by the combination of Linezolid and Ritodrine. Preterm labour/delivery [JB00] [23]
Terazosin DM3JCVS Moderate Additive hypotensive effects by the combination of Linezolid and Terazosin. Prostate hyperplasia [GA90] [20]
Tamsulosin DM5QF9V Moderate Additive hypotensive effects by the combination of Linezolid and Tamsulosin. Prostate hyperplasia [GA90] [20]
Silodosin DMJSBT6 Moderate Additive hypotensive effects by the combination of Linezolid and Silodosin. Prostate hyperplasia [GA90] [20]
Levomepromazine DMIKFEL Moderate Additive hypotensive effects by the combination of Linezolid and Levomepromazine. Psychotic disorder [6A20-6A25] [20]
Fluphenazine DMIT8LX Moderate Additive CNS depression effects by the combination of Linezolid and Fluphenazine. Psychotic disorder [6A20-6A25] [20]
Selexipag DMAHSU0 Moderate Additive hypotensive effects by the combination of Linezolid and Selexipag. Pulmonary hypertension [BB01] [20]
Tolazoline DMI40NL Moderate Additive hypotensive effects by the combination of Linezolid and Tolazoline. Pulmonary hypertension [BB01] [20]
Epoprostenol DMUTYR2 Moderate Additive hypotensive effects by the combination of Linezolid and Epoprostenol. Pulmonary hypertension [BB01] [20]
Iloprost DMVPZBE Moderate Additive hypotensive effects by the combination of Linezolid and Iloprost. Pulmonary hypertension [BB01] [20]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Linezolid and Canakinumab. Rheumatoid arthritis [FA20] [47]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Linezolid and Rilonacept. Rheumatoid arthritis [FA20] [47]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Linezolid and Golimumab. Rheumatoid arthritis [FA20] [48]
Leflunomide DMR8ONJ Major Additive myelosuppressive effects by the combination of Linezolid and Leflunomide. Rheumatoid arthritis [FA20] [37]
Mesoridazine DM2ZGAN Moderate Additive CNS depression effects by the combination of Linezolid and Mesoridazine. Schizophrenia [6A20] [20]
Thioridazine DM35M8J Moderate Additive CNS depression effects by the combination of Linezolid and Thioridazine. Schizophrenia [6A20] [20]
Perphenazine DMA4MRX Moderate Additive hypotensive effects by the combination of Linezolid and Perphenazine. Schizophrenia [6A20] [20]
Trifluoperazine DMKBYWI Moderate Additive hypotensive effects by the combination of Linezolid and Trifluoperazine. Schizophrenia [6A20] [20]
Fentanyl DM8WAHT Major Additive serotonergic effects by the combination of Linezolid and Fentanyl. Sensation disturbance [MB40] [49]
Sufentanil DMU7YEL Major Additive serotonergic effects by the combination of Linezolid and Sufentanil. Sensation disturbance [MB40] [28]
Avanafil DM75CXN Moderate Additive hypotensive effects by the combination of Linezolid and Avanafil. Sexual dysfunction [HA00-HA01] [20]
Tadalafil DMJZHT1 Moderate Additive hypotensive effects by the combination of Linezolid and Tadalafil. Sexual dysfunction [HA00-HA01] [20]
Vardenafil DMTBGW8 Moderate Additive hypotensive effects by the combination of Linezolid and Vardenafil. Sexual dysfunction [HA00-HA01] [20]
Papaverine DMCA9QP Moderate Additive hypotensive effects by the combination of Linezolid and Papaverine. Tonus and reflex abnormality [MB47] [20]
Azathioprine DMMZSXQ Moderate Additive immunosuppressive effects by the combination of Linezolid and Azathioprine. Transplant rejection [NE84] [31]
Mycophenolate mofetil DMPQAGE Moderate Altered absorption of Linezolid due to GI flora changes caused by Mycophenolate mofetil. Transplant rejection [NE84] [29]
Chlorpropamide DMPHZQE Moderate Increased risk of hypoglycemia by the combination of Linezolid and Chlorpropamide. Type 2 diabetes mellitus [5A11] [16]
Insulin-detemir DMOA4VW Moderate Increased risk of hypoglycemia by the combination of Linezolid and Insulin-detemir. Type-1/2 diabete [5A10-5A11] [16]
Insulin degludec DMPL395 Moderate Increased risk of hypoglycemia by the combination of Linezolid and Insulin degludec. Type-1/2 diabete [5A10-5A11] [16]
Chlorpheniramine DM5URA2 Moderate Additive CNS depression effects by the combination of Linezolid and Chlorpheniramine. Vasomotor/allergic rhinitis [CA08] [19]
Methdilazine DMAUHQX Moderate Additive CNS depression effects by the combination of Linezolid and Methdilazine. Vasomotor/allergic rhinitis [CA08] [20]
Carbinoxamine DMCT31R Moderate Additive CNS depression effects by the combination of Linezolid and Carbinoxamine. Vasomotor/allergic rhinitis [CA08] [19]
Brompheniramine DMFOVSD Moderate Additive CNS depression effects by the combination of Linezolid and Brompheniramine. Vasomotor/allergic rhinitis [CA08] [19]
Xylometazoline DMKV32D Moderate Decreased metabolism of Linezolid caused by Xylometazoline mediated inhibition of non-CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [34]
Acrivastine DMTIGA0 Moderate Additive CNS depression effects by the combination of Linezolid and Acrivastine. Vasomotor/allergic rhinitis [CA08] [19]
Azatadine DMZ80SB Moderate Additive CNS depression effects by the combination of Linezolid and Azatadine. Vasomotor/allergic rhinitis [CA08] [19]
Ganciclovir DM1MBYQ Moderate Additive myelosuppressive effects by the combination of Linezolid and Ganciclovir. Virus infection [1A24-1D9Z] [31]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Linezolid and Valganciclovir. Virus infection [1A24-1D9Z] [31]
⏷ Show the Full List of 179 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Diethyl phthalate E00135 6781 Plasticizing agent; Solvent
FD&C blue no. 2 E00446 2723854 Colorant
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearyl fumarate E00545 23665634 lubricant
Sunset yellow FCF E00255 17730 Colorant
Carmellose sodium E00625 Not Available Disintegrant
Crospovidone E00626 Not Available Disintegrant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 1000 E00647 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
⏷ Show the Full List of 18 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Linezolid 600 mg tablet 600 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.
2 BDDCS applied to over 900 drugs
3 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Genome sequencing of linezolid-resistant Streptococcus pneumoniae mutants reveals novel mechanisms of resistance. Genome Res. 2009 Jul;19(7):1214-23.
7 Company report (JMI Laboratories)
8 Inhibition of peptide bond formation by pleuromutilins: the structure of the 50S ribosomal subunit from Deinococcus radiodurans in complex with tiamulin. Mol Microbiol. 2004 Dec;54(5):1287-94.
9 The fused TrpEG from Streptomyces venezuelae is an anthranilate synthase, not a 2-amino-2-deoxyisochorismate [corrected] (ADIC) synthase. Ethn Dis. 2008 Spring;18(2 Suppl 2):S2-9-13.
10 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
11 The apicoplast as an antimalarial drug target. Drug Resist Updat. 2001 Jun;4(3):145-51.
12 Has nature already identified all useful antibacterial targets Curr Opin Microbiol. 2008 Oct;11(5):387-92.
13 Ribosomal RNA is the target for oxazolidinones, a novel class of translational inhibitors. RNA. 1999 Jul;5(7):939-46.
14 EDP-420, a Bicyclolide (Bridged Bicyclic Macrolide), Is Active against Mycobacterium avium. Antimicrob Agents Chemother. 2007 May; 51(5): 1666-1670.
15 Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
16 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
17 Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
18 Hendershot PE, Antal EJ, Welshman IR, Batts DH, Hopkins NK "Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr." J Clin Pharmacol 41 (2001): 563-72. [PMID: 11361053]
19 Canadian Pharmacists Association.
20 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
21 Product Information. Marplan (isocarboxazid) Roche Laboratories, Nutley, NJ.
22 Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN "Interactions between sympathomimetic amines and antidepressant agents in man." Br Med J 1 (1973): 311-5. [PMID: 4685619]
23 Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Committee on drugs, the American Academy of Allergy and Immunology. J Allergy Clin Immunol 75 (1985): 443-9. [PMID: 2858503]
24 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
25 Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005): 956-61. [PMID: 15827071]
26 Product Information. Northera (droxidopa). Chelsea Therapeutics Inc, Charlotte, NC.
27 Product Information. Cocaine Hydrochloride Nasal (cocaine nasal). Genus Lifesciences Inc., Allentown, PA.
28 Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
29 Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
30 Paladino JA "Linezolid: an oxazolidinone antimicrobial agent." Am J Health Syst Pharm 59 (2002): 2413-25. [PMID: 12503340]
31 Cerner Multum, Inc. "Australian Product Information.".
32 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
33 Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31. [PMID: 8845455]
34 Cusson JR, Goldenberg E, Larochelle P "Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans." J Clin Pharmacol 31 (1991): 462-7. [PMID: 2050833]
35 Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201. [PMID: 7756727]
36 Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6. [PMID: 219931]
37 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
38 De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5. [PMID: 4379192]
39 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
40 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
41 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
42 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
43 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
44 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
45 Filibeck DJ, Grimm D, Forman WB, Leidner BA "Metoclopramide-induced hypertensive crisis." Clin Pharm 3 (1984): 548-9. [PMID: 6541544]
46 Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN "Interactions between sympathomimetic amines and antidepressant agents in man." Br Med J 1 (1973): 311-5. [PMID: 4685619]
47 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
48 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
49 Browne B, Linter S "Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment." Br J Psychiatry 151 (1987): 210-2. [PMID: 2891392]